{"id":930,"date":"2013-07-31T21:01:55","date_gmt":"2013-07-31T19:01:55","guid":{"rendered":"http:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/201307"},"modified":"2014-01-01T12:23:52","modified_gmt":"2014-01-01T11:23:52","slug":"36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2","status":"publish","type":"post","link":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930","title":{"rendered":"36. Eur\u00f3pska CF konferencia – 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov"},"content":{"rendered":"

V oblasti v\u00fdvoja nov\u00fdch liekov bola na konferencii pozornos\u0165 zameran\u00e1 jednozna\u010dne na molekuly vyvinut\u00e9 spolo\u010dnos\u0165ou Vertex \u2013 ivacaftor (Kalydeco), lumacaftor a \u010fal\u0161ie v \u0161t\u00e1diu klinick\u00e9ho sk\u00fa\u0161ania.<\/p>\n

Ivacaftor bol v minulom roku schv\u00e1len\u00fd pre uvedenie na Americk\u00fd a Eur\u00f3psky trh pre lie\u010dbu pacientov s mut\u00e1ciou G551D. V s\u00fa\u010dastnosti s\u00fa teda k dispoz\u00edcii prv\u00e9 poznatky z klinickej praxe. Vzh\u013eadom na relat\u00edvne n\u00edzke zast\u00fapenie mut\u00e1cie G551D v pacientskej popul\u00e1cii, e\u0161te d\u00f4le\u017eitej\u0161ie s\u00fa v s\u00fa\u010dasnosti prebiehaj\u00face klinick\u00e9 \u0161t\u00fadie t\u00fdchto molek\u00fal v lie\u010dbe pacientov s naj\u010dastej\u0161ou mut\u00e1ciou F508del.<\/p>\n

Boli prezentovan\u00e9 v\u00fdsledky klinickej \u0161t\u00fadie f\u00e1zy II kombin\u00e1cie ivacaftoru a VX-661.<\/a> V \u0161t\u00fadii sa zaznamenalo \u0161tatisticky v\u00fdznamn\u00e9 zlep\u0161enie p\u013e\u00facnych funkcii, pribli\u017ene o 9%, (pri d\u00e1vke 100 a 150mg dvakr\u00e1t denne), \u010do nazna\u010duje, \u017ee liek bude \u00fa\u010dinn\u00fd. Teraz bude nasledova\u0165 f\u00e1za 3 klinickej \u0161t\u00fadie, ktor\u00e1 definit\u00edvne ur\u010d\u00ed klinick\u00fa hodnotu lieku a v pr\u00edpade pozit\u00edvnych v\u00fdsledkov bude sl\u00fa\u017ei\u0165 ako podklad pre jeho schv\u00e1lenie.<\/p>\n

T\u00e1to \u0161t\u00fadia potvrdzuje, \u017ee v\u00fdvoj sa v s\u00fa\u010dasnosti uber\u00e1 smerom ku kombinovanej terapii \u2013 lie\u010dba pacientov s mut\u00e1ciou F508del bude najpravdepodobnej\u0161ie kombin\u00e1ciou dvoch molek\u00fal. V \u010fal\u0161ej klinickej \u0161t\u00fadii bola sk\u00faman\u00e1 kombin\u00e1cia lumacaftoru a ivacaftoru, pri\u010dom v\u00fdsledky boli podobne povzbudiv\u00e9 a bude nasledova\u0165 f\u00e1za 3.<\/p>\n

Viacero lek\u00e1rskych t\u00edmov prezentovalo prv\u00e9 klinick\u00e9 sk\u00fasenosti s lie\u010dbou ivacaftorom v klinickej praxi. Napr\u00edklad Franc\u00fazska \u0161t\u00fadia z Universite Paris Descartes a Cochin Hospital prezentovan\u00e1 formou posteru kon\u0161tatovala v\u00fdrazn\u00e9 zlep\u0161enie FEV1 ako aj telesnej hmotnosti. Zlep\u0161enie FEV1 bolo najv\u00fdraznej\u0161ie pri dospel\u00fdch pacientov \u2013 viac ako 14%, u det\u00ed to bolo okolo 10%. Priemern\u00fd n\u00e1rast telesnej hmotnosti bol 3,8kg a do\u0161lo k v\u00fdrazn\u00e9mu zn\u00ed\u017eeniu koncentr\u00e1cie chloridov v pote. Tieto v\u00fdsledky s\u00fa konzistentn\u00e9 s v\u00fdsledkami prezentovan\u00fdmi v klinick\u00fdch \u0161t\u00fadi\u00e1ch ivacaftoru. \u010eal\u0161ia \u0161t\u00fadia do ktorej boli zapojen\u00e9 viacer\u00e9 CF centr\u00e1 v Brit\u00e1nii a \u00cdrsku zistila, \u017ee v\u010faka ivacaftoru sa zn\u00ed\u017eila u pacientov s G551D potreba pod\u00e1vania intraven\u00f3znych antibiot\u00edk a skr\u00e1til sa celkov\u00fd priemern\u00fd \u010das str\u00e1ven\u00fd v nemocnici.<\/p>\n

\"kalydeco\"<\/div>\n

 <\/p>\n

\u010eal\u0161ie molekuly, ktor\u00e9 boli spomenut\u00e9 na workshope venovanom v\u00fdvoju nov\u00fdch liekov boli vardenafil a ataluren. Eitan Kerem prezentoval v\u00fdsledky klinickej \u0161t\u00fadie f\u00e1zy 3 atalurenu, na ktorej sa z\u00fa\u010dastnilo 191 pacientov. V \u0161t\u00fadii mali pacienti, ktor\u00ed u\u017e\u00edvali ataluren oproti skupine s placebom mierne ni\u017e\u0161\u00ed pokles p\u013e\u00facnych funkci\u00ed.<\/p>\n

Dobrou spr\u00e1vou je, \u017ee pozit\u00edvne v\u00fdsledky \u0161t\u00fadii s ivacaftorom a lumacaftorom prin\u00e1\u0161aj\u00fa re\u00e1lny predpoklad, \u017ee kauz\u00e1lna lie\u010dba pre ve\u013ek\u00fa \u010das\u0165 pacientov \u2013 t\u00fdch \u010do maj\u00fa mut\u00e1ciu F508del je bl\u00edzko. Tou zlou \u017ee dostupnos\u0165 lie\u010dby je ot\u00e1zna, ke\u010f\u017ee spolo\u010dnos\u0165 Vertex, ktor\u00e1 lieky vyvinula, sa rozhodla za ne \u00fa\u010dtova\u0165 astronomick\u00e9 sumy. Ro\u010dn\u00e1 lie\u010dba ivacaftorom stoj\u00ed 294000 americk\u00fdch dol\u00e1rov. Mnoho pacientov, ktor\u00ed u\u017e\u00edvali ivacaftor, im bol indikovan\u00fd formou \u201ccompassionate use\u201c, t.j. ako dar farmaceutickej firmy a lie\u010dba nebola platen\u00e1 zo zdrojov zdravotn\u00e9ho poistenia.<\/p>\n

S\u00fa\u010dasn\u00e1 situ\u00e1cia je, \u017ee pois\u0165ovne v USA t\u00fato cenu akceptuj\u00fa a v Eur\u00f3pe je snaha dohodn\u00fa\u0165 sa medzi pois\u0165ov\u0148ami a Vertexom na ni\u017e\u0161ej cene, \u010do by zrejme bolo nevyhnutnos\u0165ou, ak bude lie\u010dba roz\u0161\u00edren\u00e1 na F508del pacientov.<\/p>\n","protected":false},"excerpt":{"rendered":"

V oblasti vývoja nových liekov bola na konferencii pozornosť zameraná jednoznačne na molekuly vyvinuté spoločnosťou Vertex – ivacaftor (Kalydeco), lumacaftor a ďalšie v štádiu klinického skúšania. Ivacaftor bol v minulom roku schválený pre uvedenie na Americký a Európsky trh pre … Continued<\/a><\/p>\n","protected":false},"author":7,"featured_media":1033,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"kt_blocks_editor_width":"","footnotes":""},"categories":[2],"tags":[257],"class_list":["post-930","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-informacie","tag-konferencia"],"yoast_head":"\n36. Eur\u00f3pska CF konferencia - 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov - Slan\u00e9 deti<\/title>\n<meta name=\"description\" content=\"V oblasti v\u00fdvoja nov\u00fdch liekov bola na konferencii pozornos\u0165 zameran\u00e1 jednozna\u010dne na molekuly vyvinut\u00e9 spolo\u010dnos\u0165ou Vertex \u2013 ivacaftor (Kalydeco) a \u010fal\u0161ie.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930\" \/>\n<meta property=\"og:locale\" content=\"sk_SK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"36. Eur\u00f3pska CF konferencia - 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov - Slan\u00e9 deti\" \/>\n<meta property=\"og:description\" content=\"V oblasti v\u00fdvoja nov\u00fdch liekov bola na konferencii pozornos\u0165 zameran\u00e1 jednozna\u010dne na molekuly vyvinut\u00e9 spolo\u010dnos\u0165ou Vertex \u2013 ivacaftor (Kalydeco) a \u010fal\u0161ie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930\" \/>\n<meta property=\"og:site_name\" content=\"Slan\u00e9 deti\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/slanedeti\" \/>\n<meta property=\"article:published_time\" content=\"2013-07-31T19:01:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-01-01T11:23:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/slanedeti.sk\/cms\/wp-content\/uploads\/2013\/07\/kalydeco.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1028\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Gallagher\" \/>\n<meta name=\"twitter:label1\" content=\"Autor\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gallagher\" \/>\n\t<meta name=\"twitter:label2\" content=\"Predpokladan\u00fd \u010das \u010d\u00edtania\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 min\u00faty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930\"},\"author\":{\"name\":\"Gallagher\",\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/#\\\/schema\\\/person\\\/05d1c3faf9ab837ae66dc01f490cedaa\"},\"headline\":\"36. Eur\u00f3pska CF konferencia – 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov\",\"datePublished\":\"2013-07-31T19:01:55+00:00\",\"dateModified\":\"2014-01-01T11:23:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930\"},\"wordCount\":620,\"image\":{\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/wp-content\\\/uploads\\\/2013\\\/07\\\/kalydeco.png\",\"keywords\":[\"konferencia\"],\"articleSection\":[\"Inform\u00e1cie\"],\"inLanguage\":\"sk-SK\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930\",\"url\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930\",\"name\":\"36. Eur\u00f3pska CF konferencia - 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov - Slan\u00e9 deti\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/wp-content\\\/uploads\\\/2013\\\/07\\\/kalydeco.png\",\"datePublished\":\"2013-07-31T19:01:55+00:00\",\"dateModified\":\"2014-01-01T11:23:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/#\\\/schema\\\/person\\\/05d1c3faf9ab837ae66dc01f490cedaa\"},\"description\":\"V oblasti v\u00fdvoja nov\u00fdch liekov bola na konferencii pozornos\u0165 zameran\u00e1 jednozna\u010dne na molekuly vyvinut\u00e9 spolo\u010dnos\u0165ou Vertex \u2013 ivacaftor (Kalydeco) a \u010fal\u0161ie.\",\"inLanguage\":\"sk-SK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"sk-SK\",\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\\\/930#primaryimage\",\"url\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/wp-content\\\/uploads\\\/2013\\\/07\\\/kalydeco.png\",\"contentUrl\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/wp-content\\\/uploads\\\/2013\\\/07\\\/kalydeco.png\",\"width\":1028,\"height\":720,\"caption\":\"kalydeco\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/#website\",\"url\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/\",\"name\":\"Slan\u00e9 deti\",\"description\":\"Inform\u00e1cie o cystickej fibr\u00f3ze\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sk-SK\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/#\\\/schema\\\/person\\\/05d1c3faf9ab837ae66dc01f490cedaa\",\"name\":\"Gallagher\",\"url\":\"https:\\\/\\\/slanedeti.sk\\\/cms\\\/author\\\/gallagher\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"36. Eur\u00f3pska CF konferencia - 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov - Slan\u00e9 deti","description":"V oblasti v\u00fdvoja nov\u00fdch liekov bola na konferencii pozornos\u0165 zameran\u00e1 jednozna\u010dne na molekuly vyvinut\u00e9 spolo\u010dnos\u0165ou Vertex \u2013 ivacaftor (Kalydeco) a \u010fal\u0161ie.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930","og_locale":"sk_SK","og_type":"article","og_title":"36. Eur\u00f3pska CF konferencia - 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov - Slan\u00e9 deti","og_description":"V oblasti v\u00fdvoja nov\u00fdch liekov bola na konferencii pozornos\u0165 zameran\u00e1 jednozna\u010dne na molekuly vyvinut\u00e9 spolo\u010dnos\u0165ou Vertex \u2013 ivacaftor (Kalydeco) a \u010fal\u0161ie.","og_url":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930","og_site_name":"Slan\u00e9 deti","article_publisher":"http:\/\/www.facebook.com\/slanedeti","article_published_time":"2013-07-31T19:01:55+00:00","article_modified_time":"2014-01-01T11:23:52+00:00","og_image":[{"width":1028,"height":720,"url":"https:\/\/slanedeti.sk\/cms\/wp-content\/uploads\/2013\/07\/kalydeco.png","type":"image\/png"}],"author":"Gallagher","twitter_misc":{"Autor":"Gallagher","Predpokladan\u00fd \u010das \u010d\u00edtania":"3 min\u00faty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930#article","isPartOf":{"@id":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930"},"author":{"name":"Gallagher","@id":"https:\/\/slanedeti.sk\/cms\/#\/schema\/person\/05d1c3faf9ab837ae66dc01f490cedaa"},"headline":"36. Eur\u00f3pska CF konferencia – 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov","datePublished":"2013-07-31T19:01:55+00:00","dateModified":"2014-01-01T11:23:52+00:00","mainEntityOfPage":{"@id":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930"},"wordCount":620,"image":{"@id":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930#primaryimage"},"thumbnailUrl":"https:\/\/slanedeti.sk\/cms\/wp-content\/uploads\/2013\/07\/kalydeco.png","keywords":["konferencia"],"articleSection":["Inform\u00e1cie"],"inLanguage":"sk-SK"},{"@type":"WebPage","@id":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930","url":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930","name":"36. Eur\u00f3pska CF konferencia - 3. \u010das\u0165: V\u00fdvoj nov\u00fdch liekov - Slan\u00e9 deti","isPartOf":{"@id":"https:\/\/slanedeti.sk\/cms\/#website"},"primaryImageOfPage":{"@id":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930#primaryimage"},"image":{"@id":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930#primaryimage"},"thumbnailUrl":"https:\/\/slanedeti.sk\/cms\/wp-content\/uploads\/2013\/07\/kalydeco.png","datePublished":"2013-07-31T19:01:55+00:00","dateModified":"2014-01-01T11:23:52+00:00","author":{"@id":"https:\/\/slanedeti.sk\/cms\/#\/schema\/person\/05d1c3faf9ab837ae66dc01f490cedaa"},"description":"V oblasti v\u00fdvoja nov\u00fdch liekov bola na konferencii pozornos\u0165 zameran\u00e1 jednozna\u010dne na molekuly vyvinut\u00e9 spolo\u010dnos\u0165ou Vertex \u2013 ivacaftor (Kalydeco) a \u010fal\u0161ie.","inLanguage":"sk-SK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930"]}]},{"@type":"ImageObject","inLanguage":"sk-SK","@id":"https:\/\/slanedeti.sk\/cms\/36-europska-cf-konferencia-3-cast-vyvoj-novych-liekov-2\/930#primaryimage","url":"https:\/\/slanedeti.sk\/cms\/wp-content\/uploads\/2013\/07\/kalydeco.png","contentUrl":"https:\/\/slanedeti.sk\/cms\/wp-content\/uploads\/2013\/07\/kalydeco.png","width":1028,"height":720,"caption":"kalydeco"},{"@type":"WebSite","@id":"https:\/\/slanedeti.sk\/cms\/#website","url":"https:\/\/slanedeti.sk\/cms\/","name":"Slan\u00e9 deti","description":"Inform\u00e1cie o cystickej fibr\u00f3ze","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/slanedeti.sk\/cms\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sk-SK"},{"@type":"Person","@id":"https:\/\/slanedeti.sk\/cms\/#\/schema\/person\/05d1c3faf9ab837ae66dc01f490cedaa","name":"Gallagher","url":"https:\/\/slanedeti.sk\/cms\/author\/gallagher"}]}},"_links":{"self":[{"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/posts\/930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/comments?post=930"}],"version-history":[{"count":0,"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/posts\/930\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/media\/1033"}],"wp:attachment":[{"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/media?parent=930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/categories?post=930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/slanedeti.sk\/cms\/wp-json\/wp\/v2\/tags?post=930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}